Toward of Safer Phenylbutazone Derivatives by Exploration of Toxicity Mechanism by Borges, Rosivaldo S. & Campos Rosa, Joaquín María
molecules
Article
Toward of Safer Phenylbutazone Derivatives by
Exploration of Toxicity Mechanism
Rosivaldo S. Borges 1,2,*, Ivanete C. Palheta 1, Sirlene S. B. Ota 1,2, Roberto B. Morais 1,2,
Valéria A. Barros 1,2, Ryan S. Ramos 3 , Rai C. Silva 2,4, Josivan da S. Costa 4 ,
Carlos H. T. P. Silva 5, Joaquín M. Campos 6 and Cleydson B. R. Santos 2,3,4,*
1 Núcleo de Estudos e Seleção de Moléculas Bioativas—NESBio, College of Pharmacy, Health Sciences
Institute, Federal University of Pará, Belém 66075-110, PA, Brazil; ivapalheta@gmail.com (I.C.P.);
sayuriota@gmail.com (S.S.B.O.); robertomorais16@hotmail.com.br (R.B.M.);
valbarros43@yahoo.com.br (V.A.B.)
2 Programa de Pós-Graduação em Química Medicinal e Modelagem Molecular, Health Science Institute,
Federal University of Pará, Belém 66075-110, PA, Brazil; camposchemistry@gmail.com
3 Programa de Pós-Graduação em Biodiversidade e Biotecnologia—Rede BIONORTE, Federal University of
Amapá, Macapá 68902-280, AP, Brazil; ryanquimico@hotmail.com
4 Laboratorio de Modelagem e Química Computacional—LMQC, Federal University of Amapá, Department
of Biological Sciences. Rod. Juscelino Kubitschek, Km 02, Macapá 68902-280, AP, Brazil;
josivan.chemistry@gmail.com
5 Laboratório Computacional de Química Farmacêutica, Faculdade de Ciências Farmacêuticas de Ribeirão
Preto, University of Sao Paulo, São Paulo 14040-903, SP, Brazil; tomich@fcfrp.usp.br
6 Department of Pharmaceutical Organic Chemistry, University of Granada, 18071 Granada, Spain;
jmcampos@ugr.es
* Correspondence: lqfmed@gmail.com (R.S.B.); breno@unifap.br (C.B.R.S.); Tel.: +55-96-4009-2699 (C.B.R.S.)
Academic Editor: Simone Brogi
Received: 7 October 2018; Accepted: 15 December 2018; Published: 1 January 2019


Abstract: A drug design for safer phenylbutazone was been explored by reactivity and docking
studies involving single electron transfer mechanism, as well as toxicological predictions. Several
approaches about its structural properties were performed through quantum chemistry calculations
at the B3LYP level of theory, together with the 6-31+G(d,p) basis sets. Molecular orbital and
ionization potential were associated to electron donation capacity. The spin densities contribution
showed a preferential hydroxylation at the para-positions of phenyl ring when compared to other
positions. In addition, on electron abstractions the aromatic hydroxylation has more impact than
alkyl hydroxylation. Docking studies indicate that six structures 1, 7, 8 and 13–15 have potential
for inhibiting human as well as murine COX-2, due to regions showing similar intermolecular
interactions to the observed for the control compounds (indomethacin and refecoxib). Toxicity can be
related to aromatic hydroxylation. In accordance to our calculations, the derivatives here proposed
are potentially more active as well safer than phenylbutazone and only structures 8 and 13–15 were
the most promising. Such results can explain the biological properties of phenylbutazone and support
the design of potentially safer candidates.
Keywords: phenylbutazone; DFT; electron transfer; metabolism; toxicity
1. Introduction
Phenylbutazone is a non-steroidal anti-inflammatory drug that has analgesic and antipyretic
actions and can be used in some situations related do acute pain and muscular-skeletal disorders,
such as in cases of ankylosing spondylitis and rheumatoid arthritis [1]. This medicine belongs
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to the group of pyrazolones, which are derived from enolic acid associated to its hydrogen α,
α-dicabonylic [2].
It was synthesized in 1946 and introduced into clinical practice in 1949. However, in 1980 were
attributed severe restrictions on the use of phenylbutazone in humans, because of the recognition that
such a drug induced blood dyscrasias, which includes aplastic anemia, leukopenia, agranulocytosis
and thrombocytopenia in some cases leading to death [3].
The toxicity of phenylbutazone is directly related to its mechanism of action, which shows
non-selective effect for COX-1 isoform and may act on COX-2, thus the side effects are more evident
in the organs and systems where COX-1 is found. The most known adverse reactions are diffused
gastritis, gastric ulcers, venous thrombosis, nephritis and chronic renal injury [4,5]. As their toxicity
depends on of metabolism and kinetics is a dose-dependent type, dosages up to two times above the
recommended can result in fatal protein loss enteropathy, within 10 to 14 days [6]. Also, their main
metabolites found were oxyphenbutazone and γ-hydroxy-phenylbutazone, where the first is active
and second inactive. Only 1% of the administered dose is excreted in the urine as the parent drug
while the majority (within 72%) is excreted in urine as metabolites and 10% is excreted in bile as well
as metabolites [7].
Recently we have developed a theoretical prediction model of toxicity for pyrazolone drugs for
agranulocytosis. Our study shows that this toxicity is mainly related to their ionization potential and
nucleophilicity values, on electron transfer process [8]. Nevertheless, at moment the mechanism to
phenylbutazone was not proposed. Thus, the study aimed to examine the molecular structure of
phenylbutazone derivatives in a particular biological system, obtaining means for predicting the safer
potential candidates.
2. Results and Discussion
2.1. Tautomerism Study
The relative barrier is the energy difference of the most stable derivative to the less stable, that is,
how much energy was needed to obtain the protonated form. In this study, we have investigated the
phenylbutazone (1a) and phenylbutazone tautomers (1b) shown in Figure 1, depicting the keto-enol
equilibrium for phenylbutazone. Results were obtained from quantum chemistry calculations at the
theory level B3LYP and 6-31G+(d,p) basis set for the equilibrium structures, demonstrating that the
conformation of the phenylbutazone molecule (1a) in the keto form is approximately 9.36 kcal/mol
more stable than the other one. For the anionic form of phenylbutazone we observed greater planarity
and rigidity of the five-membered ring (1b), on contrary to the proton form. In a qualitative analysis,
we can infer a greater degree of electron delocalization, which could result in the appearance of a
greater amount of resonance forms and consequent relocation of charges on the oxygen atoms.
Thus, the keto tautomer is more stable than the enol tautomer. Since phenylbutazone anion
is reported as the active form in inflammation, it could act as free radical by a one-electron
transfer mechanism, possibly via enol pathway [9]. However, despite this form to be unstable,
any changes on pH medium should induce modification of the equilibrium relative to this tautomerism.
The inflammation results in marked reductions of tissue pH by generation of acid derivatives as well
as protons [10].
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Figure 1. Tautomerism keto-enolic of phenylbutazone (1a) and phenylbutazone tautomers (1b). Figure 1. Tautomerism keto-enolic of phe l ) and phenylbutazone tautomers (1b).
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In addition, other pyrazole system showed the same behavior [11]. Hence for each calculation of
phenylbutazone derivatives was realized from the keto tautomer. These conformations were used for
electronic study of chemical reactivity and theoretical metabolism.
2.2. Molecular Simplification
The electron donation capacity for the simplified phenylbutazone derivatives (Figure 2) were
theoretically measured using HOMO, LUMO, GapL-H and ionization potential (IP) values. For the
phenylbutazone compound, simplification of the phenyl and alkyl groups was carried out in order
to investigate the structure-toxicity relationships at the pharmacophoric region: In compound 4,
the two phenyl rings were withdrawn due to the symmetry of the original molecule (phenylbutazone).
The structures shown in Figure 3 are derived from oxidative metabolism, originating two main
metabolites, through hydroxylation.
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The HOMO and LUMO values are n important paramet r of molecular structure relate to their
reactivity. They show all nucleophilic and electrophilic regions, respectively, around the molecule.
The molecule which has the higher HOMO energy has strong donating electron ability. On the
contrary, the higher LUMO value implies that the molecule is a good electron accepting compound [12].
The GapL-H values of these structures can indicate their chemical reactivity on electron transfers.
The lowest GapL-H value is related to high chemical reactivity. Phenylbutazone showed HOMO value
of −6.24 eV and GapL-H of 4.98 eV. Previous works have demonstrated a good tendency between
HOMO and IP [13]. The IP value for the phenylbutazone is 177.46 kcal/mol. Additionally, the alkyl
and phenyl moieties had been great influence on electron donation capacity for phenylbutazone
deriv tives. Indeed, ur results showed that phenyl moiety as more impact than alky group due to
HOMO decreases and by the increase of the GapL-H and IP values (Table 1).
Table 1. Theoretical properties of phenylbutazone derivatives.
Derivatives HOMO (eV) LUMO (eV) GAPL-H (eV) IP (kcal/mol)
1 −6.24 −1.25 4.98 177.46
2 −6.31 −1.31 5.01 180.32
3 −6.35 −1.30 5.05 185.11
4 −7.15 −1.21 5.94 215.45
5 −6.04 −1.20 4.83 166.43
6 −6.20 −1.22 4.99 170.12
Therefore, alkyl moieties and phenyl rings had a remarkable effect on electron donation capacity.
In fact, the inflammation prostaglandin-mediated can to oc ur from an oxidation pro ess by electron
or hydrogen transfers followed for an oxygen addition. So, structures that have high electron donation
capacity would have more inhibitory effect due to its antioxidant capacity [14].
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2.3. Theoretical Metabolism
The oxidative metabolism of phenylbutazone (1) gives two main metabolites by means of
hydroxylation, called oxyphenbutazone (5) and γ-hydroxyphenbutazone (6)—see Figure 3. The former
is active and the second one is inactive [7]. Our calculations show that any hydroxylation can be related
to changes on electronic behavior of phenylbutazone, such as electron donation capacity. However,
the alkyl hydroxylation at N-buthyl position can be related to changes on solubility due to the loss of
lipophilic interaction at the pocket of enzyme responsible for arachidonic acid oxidation.
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In fact, oxyphenbutazone (5) has demonstrated more electron donation capacity than
phenylbutazone. As we can see the best values for HOMO of −6.04 eV, GapL-H of 4.83 eV and
IP of 166.43 kcal/mol for 5. These values would be related to its biological activity [15]. Likewise, these
properties change for hydroxylated alkyl derivative 6 is few when compared to oxyphenbutazone (5).
In addition, the high electron donation capacity of oxyphenbutazone can be related to their toxicity
incre ses [15]. Th aromatic rings a e the best nucleophilic moietie especi lly due to nitrogen atoms.
As a r sult, after an electron transfer the most reactive positions can be ocalized by spin densities
calculations. It may be used to prediction a regioselective hydroxylation.
Therefore, the calculated spin density to initial electron abstraction on phenylbutazone (Figure 4)
shows the main contributions from the nitrogen atoms (0.21 and 0.22), carbon atoms at the
para-positions (0.14) and oxygen atom at the carbonyl groups (0.08). The contribution from the other
atoms is almost an order of magnitude minor. These results showed that the reactivity increase at the
para-positions (0.14) and explain the preferential regioselective radical attack of hydroxyl group to
form aromatic hydroxylated-type derivatives such as oxyphenbutazone.
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chloro moiety was added as metabolism inhibitor at para-position at the phenyl ring hydroxylation 
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Among the theoretical properties of phenylbutazone, the most remarkable are their high
nucleophility, electron donation capacity, lipophilicity and molecular volume. These values can be
observed through electronic, solubility and structural parameters in Table 2.
Phenylbutazone showed HOMO value of −6.24 eV and GapL-H of 4.98 eV. It is IP, Log P and
Vol values are 177.46 kcal/mol, 4.22 and 941.89 Å3, respectively. Based on them, nine derivatives
were proposed by the combination among phenylbutazone, edaravone [16] and antipirine (Figure 5).
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The chloro moiety was added as metabolism inhibitor at para-position at the phenyl ring hydroxylation
reactions [17].
Results obtained indicate that all proposed structures have more electron donation capacity
than phenylbutazone, in accordance to the HOMO, GapL-H, IP and ∆Eiso values. Likewise,
all structures have similar lipophilicity and high molecular volume, when compared to phenylbutazone.
Unfortunately, despite of all the proposed structures to be like actives and safer, in potential,
other properties need to be considered, such as bioavailability and other pharmacokinetic parameters.
However, validations will be completed only after synthesis and the respective biological evaluations.
In addition, all the theoretical values obtained for our derivatives are very close of the observed for
phenylbutazone and they do not violate the Lipinski RO5 rule [18].
Table 2. Theoretical properties of proposed phenylbutazone derivatives.
Derivatives HOMO(eV)
LUMO
(eV)
GAPL-H
(eV)
IP
(kcal/mol)
∆Eiso
(kcal/mol) Log P Vol (Å
3)
1 −6.24 −1.25 4.98 177.46 0 4.22 941.89
7 −6.44 −1.55 4.88 174.44 −3.01 5.26 1027.15
8 −5.83 −0.94 4.89 161.07 −16.38 3.94 979.66
9 −5.83 −0.99 4.83 159.79 −17.66 4.81 1051.55
10 −5.80 −0.97 4.83 159.54 −17.91 5.20 1119.93
11 −5.91 −1.46 4.44 159.69 −17.76 5.37 1030.56
12 −6.11 −2.21 3.90 168.09 −9.37 3.39 1010.77
13 −6.02 −2.10 3.91 167.21 −10.25 5.37 960.47
14 −6.02 −2.02 4.00 167.15 −10.30 5.37 963.55
15 −5.93 −1.90 4.02 166.03 −11.42 4.85 920.66
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2.5. Molecular Docking Study
For docking method validation, the indomethacin and rofecoxib structures with crystallographic
information were submitted to docking until the folding found by software that was similar to the
crystallographic information.
The comparison between crystallographic ligands IMN and RCX (red color) and best-predicted
docking conformation (green), can be seen in Figure 6 that show a great pose (orientation + conformation)
where the RMSD values were 0.75 and 1.04 Å for indomethacin and rofecoxib, respectively.
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prediction using the docking, affir that he t e is less t a 2.0 t e cr stall raphic
pose of ligand is considered successful. herefore, our results ith the ethodological proposal using
these parameters are optimal and satisfactory.
Using the docking methodology here selected, we have identified a potential binding mode for the
compound able to interact with the active site of COX-2, similar to the crystallographic pose observed
for indomethacin (PDB ID 4COX), that is, around the α-helix located between the amino acid residues
118–121, 348–352 and 522–526, as well as around the β-sheet located between the amino acid residues
353–354 and 527. For the ligand, it is possible to see common hydrogen bonds formed with Tyr355
and Arg120 residues. There is also a hydrophobic interaction with Val349, Ser353, Leu352, Val523 and
Ala527 residues, according to studies found in the literature [21].
Also, the interaction sites described for rofecoxib (PDB ID 5KIR) are located around the α-helix
between the amino acid residues 88–91, as well as the amino acids residues located between 352–354
and 515–519 around the β-sheet, according to studies carried out by Orlando et al. (2016) [22].
The validation was accepted despite of the minor deviation observed between the poses, because the
two crystallographic poses are possible.
In order to evaluate whether the changes made would lead to a higher binding affinity than
the inhibitor respective to each targeted COX-2 structure, that is, from the Mus musculus and
Homo sapiens, we docked each COX-2 structure, its specific ligand with phenylbutazone (structure 1)
and phenylbutazone derivatives (structures 7–15) in Auto-Dock/Vina software.
We observed that indomethacin (IMN) as ligand showed higher binding affinity (−9.5 kcal/mol)
to COX-2 (organism Mus musculus) than phenylbutazone (structure 1) and phenylbutazone derivatives
(structures 7–15). However, when comparing the structures donated in Mus musculus organism,
rofecoxib had a lower affinity value (−7.8 kcal/mol) when compared to phenylbutazone and
their derivatives.
However, the structure indicates a theoretical higher binding affinity of −9.2 kcal/mol,
when compared to the here investigated structures and it had a variation of ±0.3 kcal/mol in
comparison to indomethacin (IMN), whereas the other ones had a variation ranging from ±1.3
to ±0.4 kcal/mol. All these values are shown in Figure 7.
Furthermore, we observed that ligand RCX showed a higher binding affinity values
(−10.4 kcal/mol) to COX-2 (Homo sapiens), when compared to phenylbutazone (1) and phenylbutazone
derivatives (structures 7–15) as well. Indomethacin showed the lowest affinity (−7.7 kcal/mol).
However, compound 7 had a higher binding affinity (−9.7 kcal/mol) regarding to the studied structures
and had a variation ±0.7 kcal/mol in comparison to RCX and the other one structures had a variation
ranging from ±1.5 to ±0.8 kcal/mol.
With these data, we propose that the phenylbutazone (1) and phenylbutazone derivatives (7–15)
are able to make binding interaction on both organisms (Mus musculus and Homo sapiens). However,
1, 13–15 derivatives have greater binding affinity to enzyme from Mus musculus but 1, 7, 8, 14 and 15
derivatives showed greater binding affinity to the human enzyme.
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Figure 7. Binding affinity provided by AutoDock/Vina soft are of the phenylbutazone derivatives
(structures 1, 7–15) and standard ligands. Ligand control for COX-2 organism us musculus and Homo
sapiens were indomethacin and rofecoxib.
According to the studies of Beretta et al. (2005) [23], the examination of IC80 values of the four
non-steroidal anti-inflammatory drugs among them phenylbutazone (+134.4%) and flunixin (+29.7%).
Phenylbutazone show greater selectivity for COX-2 in accordance to 50% inhibitory concentration.
In fact, we suggested that phenylbutazone derivatives has both anti-inflammatory and peripheral
analgesic effects and Beretta et al. (2005) [23] has demonstrated that phenylbutazone and flunixin in
horses when compared to meloxicam, retains a best selectivity at higher concentrations. We can also
to observe higher interaction numbers of indomethacin which is a potent non-selective inhibitor of
the enzyme cyclooxygenase (COX), being a fundamental element of the cascade of arachidonic acid,
the metabolic pathway that allows the synthesis of prostaglandins and thromboxanes.
Figure 8 shows all interactions for individually docked structure 14 that had similar interactions
to the active sites of COX-2 (Mus musculus) for indomethacin to around the alpha helix between the
amino acids residues Ser353, Val523 and Gly526, in β-leaf the amino acids residue Ala527. There is
also a hydrophobic interaction with residues Val349, Ser353, Tyr385, Val523, Met522 and Ala527.
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All amino-acids residues between ligands with therapeutic targets COX-2 for the Mus musculus
organism are shown in Tables S1 and S2 (see supplementary material). Similarly, analyzing the
interaction sites for structure 7, as shown in the Figure 9 and comparing with the interaction sites
rofecoxib, we observed similar results between Homo sapiens and Mus musculus organism. Both active
sites of COX-2 have some amino-acid residues around the α-helix identified by the residue Arg120
and Val116, for β-leaf the amino acids residues Tyr 355 and Leu384, Ala 516 and Met522. In addition,
the residues Val523 and Ala527 were identified close to the active site.
Quantitative data of distances and binding free energies (∆G) between the phenylbutazone
derivatives and COX-2 for both receptors of Mus musculus and Homo sapiens organisms can be seen in
Tables S1–S4 (see supplementary material). It is possible to verify that, among the template structures,
such as indomethacin (IMN) and rofecoxib (RCX) inhibitors, the increase in the number of interactions
resulted in diminution of the binding free energy, which indicates a higher degree of spontaneity of
the interactions. This type of analysis provides additional information of features of the compounds to
get a better understanding of the chemical behavior for new drugs.
This effect is noticeable for phenylbutazone derivatives with binding free energy similar to the
observed for the template structures. In fact, common interactions with the amino-acids occurred in all
the analyzed structures and they can indicate that they play a relevant play in the anti-inflammatory
activity for the structures here investigated—Tables S1–S4 (see supplementary material).
Comparing phenylbutazone derivatives with the template molecules indomethacin and rofecoxib,
we can observe that diminution of the binding free energy is similar because they have two different
interactions, one with Leu352 and another with Ser353. Our results show that the interactions are a
favorable factor for lowest values of ∆G here obtained.
The alkyl or aryl interactions have strong hydrophobic characteristic and they are related to
favorable entropic factors can promote the lowering of the free energy of ligand-receptor binding and
all the tested ligands were capable of forming hydrogen interactions with residues at their respective
binding sites [24–28]. This result confirms that proposed phenylbutazone derivatives have in silico
anti-inflammatory activity via COX inhibition, as well as, in silico study is a valuable tool as a support
for in vivo assays and from the in silico analysis, mechanisms can be clarified at the molecular level.
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In the rational drug design process, availability of 3D (three-dimensional) protein structures is
crucially important. The X-ray crystallography, considered an efficient tool in determining protein 3D
poses, is a time-consuming and expensive method. In addition, certain proteins cannot be successfully
crystallized or are difficult to crystallize, for example the membrane proteins. Therefore, a very low
number of membrane proteins structures has been determined. The recent breakthroughs indicate that
NMR is indeed a very powerful tool in determining the 3D structures of membrane proteins [29–32]
but it is also time-consuming and costly. To acquire the structural information in a timely manner,
a series of 3D protein structures were developed by means of homology (or comparative) technique
and were found very useful for drug development [33–35].
2.6. Toxicological Properties
In this present study, only structures 1, 7, 8, 14 and 15 showed good results of molecular docking
as well as predictions of toxicological properties, in comparison to the results obtained for the
template molecules (Indomethacin, Refocoxib and Phenylbutazone). The toxicological properties
of the structures containing toxicity alarms are shown in Table 3. It is noted that indomethacin in the
toxicity analysis did not show any alert, a fact that could be due to the low concentration in which the
compound acts inside the active site. Analysis of the toxicological properties allowed us to observe
that all the structures point out toxicity alerts characterized as “plausible” or “acceptable”—see Table 3.
Refecoxib showed an alert of hepatotoxicity respective to furan derivatives. Many of these
compounds have been reported to cause a dose-related hepatic necrosis in rodents including
furosemide to produce midzonal to centrilobular necrosis in mice and rats [36–39]. The mechanism
of toxicity is proposed to involve oxidative ring opening of the furan ring leading to formation of
reactive intermediates, which can alkylate proteins or form adducts with DNA [40]. Evidence of liver
toxicity for furan-containing compounds in humans is limited. For example furosemide has not been
associated with liver effects in humans but it has caused jaundice and attention has been drawn to its
potential hepatotoxicity in case of high dose administration to patients with renal failure [38,41,42].
Furan is a liver toxicant and hepatocarcinogen in rodents [43,44].
The hepatotoxicity of furan and related compounds is thought to result from the formation of
chemically reactive metabolites [37,40]. The oxidative opening of the furan ring is primarily catalyzed
by cytochrome P450s and is thought to proceed via the initial formation of a furan-epoxide. The scission
of the ring leads to the formation of an electrophilic alpha, β-unsaturated dicarbonyl moiety, which
can covalently bind to macromolecules via a Michael-type addition [40].
The scope of this alert has been defined by the common structural features of the active compounds
in this class, namely the furan ring moiety. The monosubstituted 2- and 3-methylfurans are excluded
on the basis they can be readily oxidized to carboxylic acids and excreted without causing toxic effects
as supported by experimental studies in rodents [38,39]. Based on this data, carboxylic acids and their
derivatives are also excluded from the furan ring. Nitro and alkyl amine compounds are also omitted
as they are thought to induce toxicity via a different mechanism [45].
In Table 3, structures 1 and 7 are shown containing alerts of hepatotoxicity for 1,2-diphenyl-3,
5-pyrazolidinedione derivatives. During their use as non-steroidal anti-inflammatory drugs (NSAIDs),
this class has been reported to cause necrosis, steatosis and granulomas in the liver [26]. The mechanism
of hepatotoxicity is thought to be an immune-mediated reaction but a dose related intrinsic effect has
also been reported for phenylbutazone [46].
Phenylbutazone and its pharmacologically active metabolites oxyphenbutazone and kebuzone
are used as NSAIDs. They may cause various side effects including several forms of hepatic injury
occurring during treatment. In many reports of human liver toxicity by phenylbutazone (daily doses
varying from 300 mg to 800 mg) the hepatocellular injury was described as being acute and the severity
ranged from mild to moderate with or without cholestasis [36,46].
Phenylbutazone has been reported to cause steatosis, cholestasis and centrilobular necrosis,
often with ballooning degeneration and hypertrophy of Kupffer cells. Noncaseating granulomas in the
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portal and periportal areas are observed in cases of hypersensitivity to this drug [46]. In addition, it has
been reported that its active metabolites cause similar toxic effects [47,48]. Idiosyncratic liver injury
was reported after administration of feprazone, (daily dose of 600 mg) when biopsies of individuals
showed inflammation of the portal tract and parenchyma [49]. Sulfinpyrazone, an uricosuric agent,
has been described as an inducer of microsomal enzymes and shown to cause hepatic injury in isolated
cases [50].
Table 3. Predictions of the toxicological properties of structures investigated.
Structures Toxicity Prediction Alert(Lhasa Prediction) Toxicophoric Group Toxicity Alert
Toxicity Prediction
(Custom Prediction)
Indometacin - - - Nothing to declare
Refecoxib Hepatotoxicity in human,mouse and rat Furan PLAUSIBLE Nothing to declare
Phenylbutazone (1)
Hepatotoxicity in human
and mouse
1,2-Diphenyl-3,5-
pyrazolidinedione derivative CERTAIN Nothing to declare
Hepatotoxicity in rat 1,2-Diphenyl-3,5-pyrazolidinedione derivative PROBABLE
Skin sensitization in
human, mouse and rat Hydrazine or precursor PLAUSIBLE
7
Hepatotoxicity in human,
mouse and rat
1,2-Diphenyl-3,5-
pyrazolidinedione derivative PLAUSIBLE Nothing to declare
Skin sensitization in
human, mouse and rat Hydrazine or precursor PLAUSIBLE
8 Skin sensitization inhuman, mouse and rat Hydrazine or precursor PLAUSIBLE Nothing to declare
13 Skin sensitization inhuman, mouse and rat Hydrazine or precursor PLAUSIBLE Nothing to declare
14 Skin sensitization inhuman, mouse and rat Hydrazine or precursor PLAUSIBLE Nothing to declare
15 Skin sensitization inhuman, mouse and rat Hydrazine or precursor PLAUSIBLE Nothing to declare
Mice exposed to phenylbutazone by gavage (150–300 mg/kg) during a 2 years study were found
to have hepatomegaly, steatosis, cellular degeneration and coagulative necrosis [51]. The mechanism
of hepatotoxicity is not clear for this class but is reported to be mostly idiosyncratic, although the
toxicity of phenylbutazone has been reported to have two components. The intrinsic toxicity of
phenylbutazone is thought to cause cholestasis and necrosis, while cases of hypersensitivity indicated
by the presence of granulomas, are thought to be due to idiosyncratic reactions [46].
Results obtained for compounds 1, 7, 8, 13–15 indicating toxicity alerts also include coverage
for hydrazone precursors of hydrazines. The presence of a skin sensitization structural alert within
a molecule indicates the molecule has the potential to cause skin sensitization. Whether or not the
molecule will be a skin sensitizer will also depend upon its percutaneous absorption. Generally, small
lipophilic molecules are more readily absorbed into the skin and are therefore more likely to cause
sensitization [52–54]—see Table 3.
3. Materials and Methods
3.1. Theoretical
Initially, the calculations of Density Functional Theory (DFT) have also been employed in the
determination of geometry and physic-chemical properties such as partition oil-water (Log P) and
volume (V) for the phenylbutazone and its related derivatives [55]. It was done using computational
program Gaussian 09 molecular package [56]. In order to understand the interaction way at the
molecular level on phenylbutazone derivatives, their structural and electronic properties were obtained
by parameters of reactivity and theoretical properties such as energies occupied molecular orbital of
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highest energy (HOMO) and the energy unoccupied molecular orbital of lowest energy molecular
orbital (LUMO) and ionization potential (IP).
To examine the reactivity of the calculated compounds (HOMO-LUMO) GapL-H obtained by the
difference in energy between the HOMO and LUMO [57] (Equation (1)).
GapL-H = ELUMO − EHOMO (1)
The DFT method was employed, using the B3LYP functional hybrid [58,59] and the 6-31+G(d,p) basis
set to phenylbutazone derivatives (PD) which act as electron donating group. The ionization potential
(IP) was calculated as the energy difference between the neutral molecule (EPD) and the free radical
cation (EPD•+) (Equation (2)). In addition, the stabilization energy (∆Eiso) was calculated by means of
the energy’s difference between the phenylbutazone cation free radical (EPBT•+) plus neutral form of
derivatives (EPD) and the respective phenylbutazone neutral molecule (EPBT) plus cation free radical
of their derivatives (EPD•+) (Equation (3)).
IP = EPD•+ − EPD (2)
∆Eiso = (EPBT•+ + EPD) − (EPBT + EPD•+) (3)
3.2. Molecular Docking Simulations Study
The cyclooxygenase-2 (COX-2) structures resolved by X-ray diffraction was downloaded from
the Protein Data Bank (PDB) with PDB codes 4COX (Mus musculus) and 5KIR (Homo sapiens) with
resolution of 2.9 and 2.7 Å, respectively.
The control standard ligands used in docking molecular study were indomethacin (IMN) and
rofecoxib (RCX) downloaded at PDB server in sdf format ensuring the bioactive conformation.
All phenylbutazone derivatives structures were optimized using the density functional theory
method (DFT) in theory level B3LYP/6-31+G(d,p). Also, the frequencies were also calculated using
B3LYP/6-31+G(d,p) and observed that there were no negative frequencies, thereby ensuring that local
minimum energy structure [60]. The phenylbutazone derivatives and therapeutic targets structures
for molecular docking study were prepared using the software Discovery Studio 5.0 (San Diego, CA,
USA) [61], removing the water molecules and for docking validations were downloaded with the
therapeutic targets crystal structures and crystallographic inhibitors were used in molecular docking
study, as well as, in validation through of the root-mean-square deviation (RMSD) value between
the experimental data with computational data, according to studies carried out by Macêdo et al.
(2015) [62] and Federico et al. (2017) [63].
The indomethacin structure is a non-selective inhibitor (Mus musculus, PDB 4COX) and rofecoxib
structure bound to human COX-2 (Homo sapiens, PDB 5KIR) were used via AutoDock 4.2/Vina
1.1.2 (Scripps Research Ins., San Diego, CA, USA) by graphical interface Pyrx (version 0.8.30)
with default parameters via the genetic algorithm, following the protocol described previously by
Padilha et al. (2016), Pereira et al. (2018) and Costa et al. (2018) [64–66]. The population size was
100, selection-pressure was 1.1, the number of operations was 10,000, the number of islands was 1,
the niche size was 2, operator weights for migrate was 0, mutate was 100 and crossover was 100.
Spatial coordinates used for the center of the grid is described in Table 4.
Molecules 2019, 24, 143 12 of 16
Table 4. Data from protocols used for molecular docking validation purposes.
Receptor Ligand Ligand Coordinates ofthe Grid Center Grid Size (Points)
COX-2
(PDB code: 4COX)
Mus musculus
Indomethacin
X = 11.5685
Y = 12.3903
Z = 7.2430
26 x
30 y
28 z
COX-2
(PDB code: 5KIR)
Homo sapiens
Rofecoxib
X = 26.6293
Y = 40.1834
Z = 3.8484
26 x
30 y
28 z
The coordinates of the grid box located at the pocket of interest sere selected based on interactions
observed between inhibitor and enzyme, inside a 10 Å radius sphere then defined. Ten solutions
were calculated for each phenylbutazone derivatives and minimum binding energy conformations
were analyzed.
Docking studies both COX-2 and their complexed specific ligands were carried out using the
AutoDock 4.2/Vina 1.1.2 and PyRx 0.8.30 software. Spatial coordinates for PDB ID 4COX and PDB
ID 5KIR were chosen according to the interaction observed between the two COX enzymes and their
respective original ligands. The visualizations and distance of ligands interactions with COX were in
Discovery Studio 5.0.
The energy score function was used to assess the binding free energy (∆G) of interactions
between COX and phenylbutazone derivatives in PyRx 0.8.30. Analysis of each pose (conformation
+ orientation) of the ligands were also taken into account for selection of the best ∆G values as well
as binding affinity, using AutoDock 4.2/Vina 1.1.2, in order to evaluate the selectivity (and binding
affinity) of the phenylbutazone derivatives regarding the targeted COX-2 structures here used (from
Mus musculus and Homo sapiens). Both the indomethacin and rofecoxib were used as templates or
positive control controls for inhibiting COX-2 because they are known potent COX-2 inhibitors.
3.3. Toxicological Predictions
Toxicity profile of the structures was evaluated using the Deductive Estimation of Risk from
Existing Knowledge (DEREK) 10.0.2 software (Leeds, UK) [67]. We have considered DEREK alerts of
toxicity involving the human, mouse and rat species. DEREK makes the prediction of toxicity of the
structures in a qualitative way, since it is an expert system that focuses attention on the toxic action
of chemical compounds. The system performs this analysis based on implemented rules and depicts
the relationship between a structural feature and a toxicophoric group present in the compounds
as possible inducers of certain types of toxicity. It is considered that, in addition to toxicity, DEREK
can identify specific aspects related to carcinogenicity, mutagenicity, skin sensitization, irritation,
teratogenicity and neurotoxicity [68,69].
4. Conclusions
Our results using DFT/B3LYP/6-31+G(d,p) calculations showed that the molecular orbitals,
ionization potential and spin density contributions of phenylbutazone can be used to explain
their oxidation prediction and chemical reactivity. Both phenyl rings have more influence under
electron donation capacity than alkyl moiety. Aromatic hydroxylation ring has more impact on
electron donation capacity than alkyl hydroxylation. The spin densities contribution showed that a
regioselective hydroxylation is more favored at the para-positions of phenyl ring than other positions.
Docking results here obtained indicate that compounds 1, 7, 8 and 13–15 have potential capacity
of COX-2 inhibition in human and mice enzyme as well, due to contain similar interactions to the
observed for the templates or control compounds (indomethacin and refecoxib). The toxicity could be
here related to an aromatic hydroxylation. In accordance to our calculations, the proposed derivatives
are potentially more active and safer than phenylbutazone and only compounds 8 and 13–15 were the
Molecules 2019, 24, 143 13 of 16
most promising. These results could explain the biological properties observed for phenylbutazone
and they support the design of novel and safer derivative candidates.
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